March 18 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved UK-based Orchard Therapeutics' gene therapy for the treatment of children with a rare hereditary disease called metachromatic leukodystrophy (MLD). (Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,634 JPY | -1.92% | -1.24% | +11.16% |
07/05 | Kyowa Kirin's Profit Up 15% in Q1 | MT |
06/05 | Kyowa Kirin Buys Back Shares for 5.6 Billion Yen in April | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,706 PTS | -1.45% | -1.34% | - | ||
2,634 JPY | -1.92% | -1.24% | 9.27B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.16% | 9.27B | |
+8.08% | 71.94B | |
-11.55% | 5.13B | |
+48.05% | 4.66B | |
+5.09% | 3.97B | |
-14.74% | 2.55B | |
+18.90% | 2.41B | |
-24.89% | 2.36B | |
+21.45% | 2.21B | |
+7.64% | 1.71B |
- Stock Market
- Equities
- 4151 Stock
- News Kyowa Kirin Co. Ltd.
- US approves first gene therapy for rare genetic disease